{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T15:30:47Z","timestamp":1787671847225,"version":"build-2736575974"},"reference-count":95,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ymgme.2026.110129","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T23:58:56Z","timestamp":1776383936000},"page":"110129","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Glycoproteinoses: Clinical features, therapeutic landscape, and regulatory pathways in rare lysosomal disorders"],"prefix":"10.1016","volume":"148","author":[{"given":"Krista","family":"Casazza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia","family":"Kimonis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester B.","family":"Whitley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanine R.","family":"Jarnes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2026.110129_bb0005","unstructured":"Freeze HH, Steet R, Suzuki T, Schnaar RL. Chapter 44Genetic Disorders of Glycan Degradation. Essent Glycobiol Internet 4th Ed. 2022. Available from: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK579991\/ doi:https:\/\/doi.org\/10.1101\/glycobiology.4e.44."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110129_bb0010","doi-asserted-by":"crossref","first-page":"34","DOI":"10.3390\/biology13010034","article-title":"Lysosomal dysfunction: connecting the dots in the landscape of human diseases","volume":"13","author":"Uribe-Carretero","year":"2024","journal-title":"Biology"},{"key":"10.1016\/j.ymgme.2026.110129_bb0015","author":"ISMRD"},{"issue":"1","key":"10.1016\/j.ymgme.2026.110129_bb0020","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-025-03979-8","article-title":"Inherited metabolic disorders: presentation, clinical types, laboratory diagnosis and genetic markers","volume":"20","author":"Ijaz","year":"2025","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110129_bb0025","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.12833","article-title":"Unifying biology of neurodegeneration in lysosomal storage diseases","volume":"48","author":"Ludlaim","year":"2025","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110129_bb0030","first-page":"28","article-title":"Hematological findings in lysosomal storage disorders: a perspective from the medical laboratory","volume":"33","author":"Leal","year":"2022","journal-title":"EJIFCC"},{"key":"10.1016\/j.ymgme.2026.110129_bb0035","series-title":"Disorders of Glycoprotein Degradation: \u03b1-Mannosidosis, \u03b2-Mannosidosis, Fucosidosis, and Sialidosis","author":"Thomas","year":"2019"},{"issue":"2","key":"10.1016\/j.ymgme.2026.110129_bb0040","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.beem.2014.12.001","article-title":"Neuronopathic lysosomal storage disorders: approaches to treat the central nervous system","volume":"29","author":"Scarpa","year":"2015","journal-title":"Best Pract. Res. Clin. Endocrinol. Metab."},{"key":"10.1016\/j.ymgme.2026.110129_bb0045","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1146\/annurev-med-122313-085916","article-title":"Lysosomal storage diseases: from pathophysiology to therapy","volume":"66","author":"Parenti","year":"2015","journal-title":"Annu. Rev. Med."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110129_bb0050","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/s41572-018-0025-4","article-title":"Lysosomal storage diseases","volume":"4","author":"Platt","year":"2018","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ymgme.2026.110129_bb0055","series-title":"Lamzede (Velmanase Alfa): EPAR \u2013 Product Information","author":"European Medicines Agency","year":"2018"},{"key":"10.1016\/j.ymgme.2026.110129_bb0060","author":"European Medicines Agency"},{"key":"10.1016\/j.ymgme.2026.110129_bb0065","doi-asserted-by":"crossref","DOI":"10.3389\/fped.2023.1199489","article-title":"Outcomes after HSCT for mucolipidosis II (i-cell disease) caused by novel compound heterozygous GNPTAB mutations","volume":"11","author":"He","year":"2023","journal-title":"Front. Pediatr."},{"key":"10.1016\/j.ymgme.2026.110129_bb0070","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3389\/fped.2019.00433","article-title":"Hematopoietic stem cell transplantation in inborn errors of metabolism","volume":"7","author":"Tan","year":"2019","journal-title":"Front. Pediatr."},{"issue":"4","key":"10.1016\/j.ymgme.2026.110129_bb0075","doi-asserted-by":"crossref","DOI":"10.1002\/pro.70080","article-title":"A new view of missense mutations in \u03b1-mannosidosis using molecular dynamics conformational ensembles","volume":"34","author":"Mandl","year":"2025","journal-title":"Protein Sci."},{"issue":"3","key":"10.1016\/j.ymgme.2026.110129_bb0080","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2025.109042","article-title":"Analysis of serum oligosaccharides by UPLC-MS\/MS for diagnosis and treatment monitoring of patients with alpha-mannosidosis","volume":"144","author":"Kubaski","year":"2025","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2026.110129_bb0085","author":"Ficicioglu"},{"key":"10.1016\/j.ymgme.2026.110129_bb0090","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1186\/1750-1172-8-88","article-title":"Natural history of alpha mannosidosis a longitudinal study","volume":"8","author":"Beck","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110129_bb0095","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s13023-020-01549-8","article-title":"The SPARKLE registry: protocol for an international prospective cohort study in patients with alpha-mannosidosis","volume":"15","author":"Hennermann","year":"2020","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110129_bb0100","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1136\/jmg.2009.067736","article-title":"Phenotype and genotype in mucolipidoses II and III alpha\/beta: a study of 61 probands","volume":"47","author":"Cathey","year":"2010","journal-title":"J. Med. Genet."},{"issue":"2","key":"10.1016\/j.ymgme.2026.110129_bb0105","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1038\/s41556-023-01339-x","article-title":"Innate immune sensing of lysosomal dysfunction drives multiple lysosomal storage disorders","volume":"26","author":"Wang","year":"2024","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ymgme.2026.110129_bb0110","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1750-1172-3-21","article-title":"Alpha-mannosidosis","volume":"3","author":"Malm","year":"2008","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2026.110129_bb0115","article-title":"Long-term outcome of patients with alpha-mannosidosis - a single center study","volume":"30","author":"Lipi\u0144ski","year":"2022","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"9","key":"10.1016\/j.ymgme.2026.110129_bb0120","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1212\/01.WNL.0000143057.25471.4F","article-title":"Adult alpha-mannosidosis: clinical progression in the absence of demyelination","volume":"63","author":"Gutschalk","year":"2004","journal-title":"Neurology"},{"key":"10.1016\/j.ymgme.2026.110129_bb0125","article-title":"Disease progression of alpha-mannosidosis and impact on patients and carers - a UK natural history survey","volume":"20","author":"Adam","year":"2019","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110129_bb0130","doi-asserted-by":"crossref","DOI":"10.1186\/s13023-022-02422-6","article-title":"Mortality in patients with alpha-mannosidosis: a review of patients data and the literature","volume":"17","author":"Hennermann","year":"2022","journal-title":"Orphanet J. Rare Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110129_bb0135","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.12799","article-title":"Extended long-term efficacy and safety of velmanase alfa treatment up to 12years in patients with alpha-mannosidosis","volume":"48","author":"Guffon","year":"2025","journal-title":"J. Inherit. Metab. Dis."},{"issue":"6","key":"10.1016\/j.ymgme.2026.110129_bb0140","doi-asserted-by":"crossref","DOI":"10.3390\/cells9061411","article-title":"The role of hematopoietic cell transplant in the glycoprotein diseases","volume":"9","author":"Naumchik","year":"2020","journal-title":"Cells"},{"issue":"3","key":"10.1016\/j.ymgme.2026.110129_bb0145","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/bmt.2011.99","article-title":"Allogeneic hematopoietic SCT for alpha-mannosidosis: an analysis of 17 patients","volume":"47","author":"Mynarek","year":"2012","journal-title":"Bone Marrow Transplant."},{"issue":"4","key":"10.1016\/j.ymgme.2026.110129_bb0150","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.70047","article-title":"Outcome of haemopoietic stem cell transplantation in 21 patients with alpha-Mannosidosis","volume":"48","author":"\u0160\u00e1h\u00f3 R","year":"2025","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2026.110129_bb0155","article-title":"Disease profile in a cohort of Brazilian patients diagnosed with alpha-mannosidosis","volume":"43","author":"Poswar F de O","year":"2025","journal-title":"Mol. Genet. Metab. Rep."},{"issue":"5","key":"10.1016\/j.ymgme.2026.110129_bb0160","doi-asserted-by":"crossref","first-page":"393","DOI":"10.5144\/0256-4947.2004.393","article-title":"Beta-mannosidae deficiency in two mentally retarded girls with intractable seizures","volume":"24","author":"Cherian","year":"2004","journal-title":"Ann. Saudi Med."},{"key":"10.1016\/j.ymgme.2026.110129_bb0165","first-page":"93","article-title":"A clinically severe variant of \u03b2-Mannosidosis, presenting with neonatal onset epilepsy with subsequent evolution of hydrocephalus","volume":"11","author":"Broomfield","year":"2013","journal-title":"JIMD Rep."},{"issue":"2","key":"10.1016\/j.ymgme.2026.110129_bb0170","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.ymgme.2020.04.001","article-title":"\u0391-Mannosidosis - an underdiagnosed lysosomal storage disease in individuals with an \u201cMPS-like\u201d phenotype","volume":"130","author":"Wiesinger","year":"2020","journal-title":"Mol. Genet. Metab."},{"issue":"7","key":"10.1016\/j.ymgme.2026.110129_bb0175","article-title":"Biochemical and clinical response after umbilical cord blood transplant in a boy with early childhood-onset beta-mannosidosis","volume":"7","author":"Lund TC","year":"2019","journal-title":"Mol. Genet. Genomic Med."},{"key":"10.1016\/j.ymgme.2026.110129_bb0180","article-title":"Oral manifestation and dental treatment of pediatric patient with beta-mannosidosis: a case report","volume":"9","author":"Alshoraim MA","year":"2021","journal-title":"SAGE Open Med. Case Rep."},{"issue":"2","key":"10.1016\/j.ymgme.2026.110129_bb0185","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4103\/jpn.JPN_65_20","article-title":"Familial global developmental delay secondary to \u03b2-Mannosidosis","volume":"16","author":"Gowda","year":"2021","journal-title":"J. Pediatr. Neurosci."},{"issue":"6","key":"10.1016\/j.ymgme.2026.110129_bb0190","doi-asserted-by":"crossref","DOI":"10.1212\/NXG.0000000000200317","article-title":"Expanding the phenotype spectrum of \u03b2-Mannosidosis","volume":"11","author":"Martin Rios AM","year":"2025","journal-title":"Neurol. Genet."},{"issue":"4","key":"10.1016\/j.ymgme.2026.110129_bb0195","doi-asserted-by":"crossref","DOI":"10.3390\/biom11040611","article-title":"Gene therapy for lysosomal storage disorders: ongoing studies and clinical development","volume":"11","author":"Massaro G","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.ymgme.2026.110129_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fgene.2023.1064924","article-title":"Gene therapy for lysosomal storage diseases: current clinical trial prospects","volume":"14","author":"Kido","year":"2023","journal-title":"Front. Genet."},{"issue":"5","key":"10.1016\/j.ymgme.2026.110129_bb0205","first-page":"425","article-title":"A cross-sectional natural history study of aspartylglucosaminuria","volume":"63","author":"Goodspeed","year":"2022","journal-title":"JIMD Rep."},{"key":"10.1016\/j.ymgme.2026.110129_bb0210","series-title":"GeneReviews Internet","article-title":"Aspartylglucosaminuria","author":"Goodspeed","year":"2024"},{"issue":"5","key":"10.1016\/j.ymgme.2026.110129_bb0215","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1177\/0883073820980904","article-title":"Aspartylglucosaminuria: clinical presentation and potential therapies","volume":"36","author":"Goodspeed","year":"2021","journal-title":"J. Child Neurol."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110129_bb0220","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/ajmg.1320380125","article-title":"Fucosidosis revisited: a review of 77 patients","volume":"38","author":"Willems","year":"1991","journal-title":"Am. J. Med. Genet."},{"issue":"4","key":"10.1016\/j.ymgme.2026.110129_bb0225","first-page":"430","article-title":"A case of fucosidosis type II: diagnosed with dysmorphological and radiological findings","volume":"56","author":"K\u0131l\u0131\u00e7","year":"2014","journal-title":"Turk. J. Pediatr."},{"issue":"11","key":"10.1016\/j.ymgme.2026.110129_bb0230","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3390\/genes11111383","article-title":"Fucosidosis-clinical manifestation, long-term outcomes, and genetic profile-review and case series","volume":"11","author":"Stepien","year":"2020","journal-title":"Genes"},{"issue":"1","key":"10.1016\/j.ymgme.2026.110129_bb0235","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3390\/ijms26010353","article-title":"Fucosidosis: a review of a rare disease","volume":"26","author":"Pekdemir","year":"2025","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.ymgme.2026.110129_bb0240","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1111\/joim.13635","article-title":"Uncovering genetic causes of hypophosphatemia","volume":"293","author":"Puente-Ruiz","year":"2023","journal-title":"J. Intern. Med."},{"issue":"7","key":"10.1016\/j.ymgme.2026.110129_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/biom11070964","article-title":"Lysosomal storage disorders: molecular basis and therapeutic approaches","volume":"11","author":"Moro","year":"2021","journal-title":"Biomolecules"},{"issue":"9","key":"10.1016\/j.ymgme.2026.110129_bb0250","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1016\/j.ymthe.2024.06.003","article-title":"Biomarkers for gene therapy clinical trials of lysosomal storage disorders","volume":"32","author":"Rossi","year":"2024","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"issue":"2","key":"10.1016\/j.ymgme.2026.110129_bb0255","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/21678707.2016.1266933","article-title":"Galactosialidosis: historic aspects and overview of investigated and emerging treatment options","volume":"5","author":"Annunziata","year":"2017","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/j.ymgme.2026.110129_bb0260","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1172-8-114","article-title":"Galactosialidosis: review and analysis of CTSA gene mutations","volume":"8","author":"Caciotti","year":"2013","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2026.110129_bb0265","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1016\/j.omtm.2021.10.007","article-title":"AAV-mediated gene therapy for galactosialidosis: a long-term safety and efficacy study","volume":"23","author":"Hu","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymgme.2026.110129_bb0270","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.omtm.2020.11.012","article-title":"Galactosialidosis: preclinical enzyme replacement therapy in a mouse model of the disease, a proof of concept","volume":"20","author":"Cadaoas","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"issue":"18","key":"10.1016\/j.ymgme.2026.110129_bb0275","doi-asserted-by":"crossref","first-page":"6812","DOI":"10.3390\/ijms21186812","article-title":"Mucolipidoses overview: past, present, and future","volume":"21","author":"Khan","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"11","key":"10.1016\/j.ymgme.2026.110129_bb0280","doi-asserted-by":"crossref","first-page":"438","DOI":"10.3345\/kjp.2012.55.11.438","article-title":"A case of mucolipidosis II presenting with prenatal skeletal dysplasia and severe secondary hyperparathyroidism at birth","volume":"55","author":"Heo","year":"2012","journal-title":"Korean J. Pediatr."},{"issue":"12","key":"10.1016\/j.ymgme.2026.110129_bb0285","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1007\/s00247-016-3673-0","article-title":"Early characteristic radiographic changes in mucolipidosis II","volume":"46","author":"Lai","year":"2016","journal-title":"Pediatr. Radiol."},{"key":"10.1016\/j.ymgme.2026.110129_bb0290","series-title":"GeneReviews\u00ae","article-title":"GNPTAB-Related Disorders","author":"Leroy","year":"1993"},{"issue":"11","key":"10.1016\/j.ymgme.2026.110129_bb0295","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1038\/s41436-021-01244-4","article-title":"Mucolipidosis type II and type III: a systematic review of 843 published cases","volume":"23","author":"Dogterom","year":"2021","journal-title":"Genet. Med."},{"issue":"12","key":"10.1016\/j.ymgme.2026.110129_bb0300","doi-asserted-by":"crossref","DOI":"10.3390\/jcm12124114","article-title":"CNS manifestations in mucolipidosis type II-a retrospective analysis of longitudinal data on neurocognitive development and neuroimaging in eleven patients","volume":"12","author":"Ammer","year":"2023","journal-title":"J. Clin. Med."},{"issue":"5","key":"10.1016\/j.ymgme.2026.110129_bb0305","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s10545-018-0186-z","article-title":"Mucolipidosis type III, a series of adult patients","volume":"41","author":"Oussoren","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"issue":"24","key":"10.1016\/j.ymgme.2026.110129_bb0310","doi-asserted-by":"crossref","first-page":"6233","DOI":"10.1038\/s44318-024-00310-2","article-title":"New players and targets in mannose 6-phosphate-dependent lysosomal sorting","volume":"43","author":"Zubkov","year":"2024","journal-title":"EMBO J."},{"issue":"2","key":"10.1016\/j.ymgme.2026.110129_bb0315","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s40265-025-02145-5","article-title":"Current and emerging therapies for lysosomal storage disorders","volume":"85","author":"Abelleyra Lastoria","year":"2025","journal-title":"Drugs"},{"issue":"Suppl. 1","key":"10.1016\/j.ymgme.2026.110129_bb0320","first-page":"91","article-title":"Hematopoietic stem cell transplant for lysosomal storage diseases","volume":"11","author":"Lund","year":"2013","journal-title":"Pediatr. Endocrinol. Rev. PER"},{"issue":"11","key":"10.1016\/j.ymgme.2026.110129_bb0325","doi-asserted-by":"crossref","first-page":"1847","DOI":"10.1016\/j.bbmt.2014.06.019","article-title":"Outcomes after hematopoietic stem cell transplantation for children with i-cell disease","volume":"20","author":"Lund","year":"2014","journal-title":"Biol. Blood Marrow Transplant."},{"key":"10.1016\/j.ymgme.2026.110129_bb0330","series-title":"Biomarker Working Group. BEST (Biomarkers, EndpointS, and other Tools)","author":"FDA-NIH","year":"2016"},{"issue":"6","key":"10.1016\/j.ymgme.2026.110129_bb0335","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1002\/mas.21688","article-title":"Quantitative clinical glycomics strategies: a guide for selecting the best analysis approach","volume":"41","author":"Patabandige","year":"2022","journal-title":"Mass Spectrom. Rev."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110129_bb0340","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1186\/s13023-024-03431-3","article-title":"Two cases of type i sialidosis and a literature review","volume":"19","author":"Ding","year":"2024","journal-title":"Orphanet J. Rare Dis."},{"issue":"2","key":"10.1016\/j.ymgme.2026.110129_bb0345","first-page":"29","article-title":"Sialidosis: a review of morphology and molecular biology of a rare pediatric disorder","volume":"8","author":"Khan","year":"2018","journal-title":"Diagn Basel Switz."},{"issue":"8","key":"10.1016\/j.ymgme.2026.110129_bb0350","doi-asserted-by":"crossref","first-page":"8031","DOI":"10.3390\/cimb46080475","article-title":"Neuraminidase-1 (NEU1): biological roles and therapeutic relevance in human disease","volume":"46","author":"Du","year":"2024","journal-title":"Curr. Issues Mol. Biol."},{"issue":"5","key":"10.1016\/j.ymgme.2026.110129_bb0355","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1002\/jimd.12615","article-title":"Advances in therapies for neurological lysosomal storage disorders","volume":"46","author":"Ellison","year":"2023","journal-title":"J. Inherit. Metab. Dis."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110129_bb0360","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s10038-003-0098-z","article-title":"Structural and immunocytochemical studies on alpha-N-acetylgalactosaminidase deficiency (Schindler\/Kanzaki disease)","volume":"49","author":"Sakuraba","year":"2004","journal-title":"J. Hum. Genet."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110129_bb0365","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1007\/s10545-006-0470-1","article-title":"A new infantile case of alpha-N-acetylgalactosaminidase deficiency. Cardiomyopathy as a presenting symptom","volume":"30","author":"Chab\u00e1s","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"issue":"4","key":"10.1016\/j.ymgme.2026.110129_bb0370","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/BF01799512","article-title":"Schindler disease: an inherited neuroaxonal dystrophy due to alpha-N-acetylgalactosaminidase deficiency","volume":"13","author":"Desnick","year":"1990","journal-title":"J. Inherit. Metab. Dis."},{"issue":"12","key":"10.1016\/j.ymgme.2026.110129_bb0375","first-page":"2982","article-title":"Schindler disease\/Kanzaki disease","volume":"53","author":"Kanzaki","year":"1995","journal-title":"Nihon Rinsho Jpn. J. Clin. Med."},{"key":"10.1016\/j.ymgme.2026.110129_bb0380","first-page":"372","article-title":"[Schindler disease\/Kanzaki disease [alpha-N-acetylgalactosaminidase deficiency]]","volume":"19 Pt 2","author":"Kanzaki","year":"1998","journal-title":"Ryoikibetsu Shokogun Shirizu"},{"issue":"2","key":"10.1016\/j.ymgme.2026.110129_bb0385","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1046\/j.1365-2133.2001.04028.x","article-title":"A new case of alpha-N-acetylgalactosaminidase deficiency with angiokeratoma corporis diffusum, with m\u00e9ni\u00e8res syndrome and without mental retardation","volume":"144","author":"Kodama","year":"2001","journal-title":"Br. J. Dermatol."},{"issue":"11","key":"10.1016\/j.ymgme.2026.110129_bb0390","article-title":"A new case of Schindler disease","volume":"6","author":"Castro","year":"2019","journal-title":"Eur. J. Case Rep. Intern. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2026.110129_bb0395","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/j.jmb.2009.08.021","article-title":"The 1.9 a structure of human alpha-N-acetylgalactosaminidase: the molecular basis of Schindler and Kanzaki diseases","volume":"393","author":"Clark","year":"2009","journal-title":"J. Mol. Biol."},{"issue":"5","key":"10.1016\/j.ymgme.2026.110129_bb0400","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1172\/JCI114901","article-title":"Schindler disease: the molecular lesion in the alpha-N-acetylgalactosaminidase gene that causes an infantile neuroaxonal dystrophy","volume":"86","author":"Wang","year":"1990","journal-title":"J. Clin. Invest."},{"issue":"2","key":"10.1016\/j.ymgme.2026.110129_bb0405","first-page":"145","article-title":"A case of n-acetyl galactosaminidase deficiency (schindler disease) associated with autism","volume":"32","author":"Blanchon","year":"2002","journal-title":"J. Autism Dev. Disord."},{"issue":"6","key":"10.1016\/j.ymgme.2026.110129_bb0410","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1007\/s10545-018-0185-0","article-title":"Efficacy and safety of velmanase alfa in the treatment of patients with alpha-mannosidosis: results from the core and extension phase analysis of a phase III multicentre, double-blind, randomised, placebo-controlled trial","volume":"41","author":"Borgwardt","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2026.110129_bb0415","doi-asserted-by":"crossref","DOI":"10.3389\/fddev.2023.1082672","article-title":"Transferrin receptor-targeting property of pabinafusp alfa facilitates its uptake by various types of human brain-derived cells in vitro","volume":"3","author":"Fukatsu","year":"2023","journal-title":"Front Drug Deliv."},{"issue":"545","key":"10.1016\/j.ymgme.2026.110129_bb0420","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aay1163","article-title":"Brain delivery and activity of a lysosomal enzyme using a blood-brain barrier transport vehicle in mice","volume":"12","author":"Ullman","year":"2020","journal-title":"Sci. Transl. Med."},{"issue":"2","key":"10.1016\/j.ymgme.2026.110129_bb0425","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.rehab.2014.01.002","article-title":"The assessment and treatment of postural disorders in cerebellar ataxia: a systematic review","volume":"57","author":"Marquer","year":"2014","journal-title":"Ann. Phys. Rehabil. Med."},{"issue":"5","key":"10.1016\/j.ymgme.2026.110129_bb0430","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1007\/s12311-024-01707-9","article-title":"Psychometric validation of the modified functional scale for the assessment and rating of ataxia (f-SARA) in patients with spinocerebellar ataxia","volume":"23","author":"Potashman","year":"2024","journal-title":"Cerebellum"},{"issue":"1","key":"10.1016\/j.ymgme.2026.110129_bb0435","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1002\/cpt.3661","article-title":"Participants in the FDAs biomarker qualification program","volume":"118","author":"Shahzad","year":"2025","journal-title":"Clin. Pharmacol. Ther."},{"issue":"3","key":"10.1016\/j.ymgme.2026.110129_bb0440","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1177\/1535370217743949","article-title":"Preclinical biomarker qualification","volume":"243","author":"Sauer","year":"2018","journal-title":"Exp. Biol. Med."},{"issue":"3","key":"10.1016\/j.ymgme.2026.110129_bb0445","doi-asserted-by":"crossref","DOI":"10.1101\/mcs.a003954","article-title":"\u0392-Mannosidosis caused by a novel homozygous intragenic inverted duplication in MANBA","volume":"5","author":"Blomqvist","year":"2019","journal-title":"Cold Spring Harb. Mol. Case Stud."},{"issue":"4","key":"10.1016\/j.ymgme.2026.110129_bb0450","doi-asserted-by":"crossref","first-page":"795","DOI":"10.24953\/turkjped.2021.4852","article-title":"Fucosidosis: clinical and molecular findings of Turkish patients","volume":"64","author":"\u015eanl\u0131","year":"2022","journal-title":"Turk. J. Pediatr."},{"issue":"2","key":"10.1016\/j.ymgme.2026.110129_bb0455","doi-asserted-by":"crossref","DOI":"10.3390\/genes16020151","article-title":"Genetic insights and clinical implications of NEU1 mutations in sialidosis","volume":"16","author":"Peng","year":"2025","journal-title":"Genes"},{"issue":"7","key":"10.1016\/j.ymgme.2026.110129_bb0460","first-page":"842","article-title":"The lysosomal storage disorders mucolipidosis type II, type III alpha\/beta, and type III gamma: update on GNPTAB and GNPTG mutations","volume":"40","author":"Velho","year":"2019","journal-title":"Hum. Mutat."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110129_bb0465","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13023-016-0544-6","article-title":"Aspartylglycosaminuria: a review","volume":"11","author":"Arvio","year":"2016","journal-title":"Orphanet J. Rare Dis."},{"issue":"12","key":"10.1016\/j.ymgme.2026.110129_bb0470","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/s41573-019-0036-1","article-title":"Lysosomes as a therapeutic target","volume":"18","author":"Bonam","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ymgme.2026.110129_bb0475","doi-asserted-by":"crossref","DOI":"10.1016\/j.imr.2024.101119","article-title":"Patient-focused drug development and real world study","volume":"14","author":"Hu","year":"2025","journal-title":"Integr. Med. Res."}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226004129?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719226004129?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T14:59:32Z","timestamp":1787669972000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719226004129"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":95,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S1096719226004129"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.110129","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Glycoproteinoses: Clinical features, therapeutic landscape, and regulatory pathways in rare lysosomal disorders","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2026.110129","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"110129"}}